Alterations in cytokine expression associated with inflammation have long been observed in individuals with immune-mediated disease. Clinical trials carried out almost a decade ago were the first ...
Ruxolitinib phosphate is under clinical development by Incyte and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome.